EMEA-001984-PIP02-20
Key facts
Active substance |
Sparsentan
|
Therapeutic area |
Uro-nephrology
|
Decision number |
P/0021/2021
|
PIP number |
EMEA-001984-PIP02-20
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of focal segmental glomerulosclerosis
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Vifor (International) AG
Email: sparsentan_ra@viforpharma.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|